1. Home
  2. AX vs DNTH Comparison

AX vs DNTH Comparison

Compare AX & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Axos Financial Inc.

AX

Axos Financial Inc.

HOLD

Current Price

$99.14

Market Cap

5.0B

Sector

Finance

ML Signal

HOLD

Logo Dianthus Therapeutics Inc.

DNTH

Dianthus Therapeutics Inc.

HOLD

Current Price

$104.31

Market Cap

4.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AX
DNTH
Founded
1999
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Savings Institutions
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.0B
4.5B
IPO Year
2004
2018

Fundamental Metrics

Financial Performance
Metric
AX
DNTH
Price
$99.14
$104.31
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
7
13
Target Price
$103.14
$121.00
AVG Volume (30 Days)
394.0K
1.1M
Earning Date
04-30-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
6.33
N/A
Revenue
$65,789,000.00
$2,036,000.00
Revenue This Year
$24.76
N/A
Revenue Next Year
$10.86
$29.48
P/E Ratio
$15.96
N/A
Revenue Growth
1.78
N/A
52 Week Low
$74.89
$18.08
52 Week High
$102.18
$102.37

Technical Indicators

Market Signals
Indicator
AX
DNTH
Relative Strength Index (RSI) 63.49 64.02
Support Level $85.44 $79.27
Resistance Level $100.42 N/A
Average True Range (ATR) 2.51 5.96
MACD 0.06 0.52
Stochastic Oscillator 67.48 97.94

Price Performance

Historical Comparison
AX
DNTH

About AX Axos Financial Inc.

Axos Financial Inc is a bank holding company that operates through its bank subsidiary, BofI Federal Bank, a nationwide bank that provides financing for single and multifamily residential properties, small to medium-size businesses in certain sectors, and selected specialty finance receivables. Its operating segments are banking business segment and securities business segment. The bank distributed its products through a wide range of retail distribution channels, including only banking brands, affinity groups, and sales teams, among others. The majority of the bank's mortgage exposure is titled toward the state of California, particularly its southern region. Net interest income is a majority of the bank's revenue.

About DNTH Dianthus Therapeutics Inc.

Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.

Share on Social Networks: